When does Vertex Pharmaceuticals Incorporated (VRTX) report earnings? On Nov 2, 2026, after the close

Of its last 12 earnings announcements: 12 after the close. Each one comes from the 8-K with item 2.02 that Vertex Pharmaceuticals filed with the SEC, paired with the 10-Q or 10-K for that same quarter: 66 quarters since Apr 21, 2010, and every row links to its filing.

Next announced date: Nov 2, 2026, after the close. It comes from the company through the public Nasdaq calendar, not from the SEC: it is a scheduled date and companies do move it. Everything else on this page already happened, with its filing attached.

The last 20 quarters, one by one

"Lead": trading sessions between the announcement and the full quarterly report to the SEC (10-Q, or 10-K at fiscal year end). For Vertex Pharmaceuticals, a median of 1 session over the last 12 quarters.

The table shows the 20 most recent quarters. All 66 are in the CSV, with the same columns and one row per quarter.

Download all 66 VRTX quarters as CSV → Free, no account.

How Vertex Pharmaceuticals shares moved on their latest earnings

Over the 8 announcements with prices in this table, VRTX rose 3 times and fell 5 times; the median move, ignoring sign, was 4.4%, against 0.8% for SPY over the same windows. The largest, −20.6%, came with the results of Aug 4, 2025. Reported EPS beat the consensus estimate in 3 of the 5 quarters with an estimate.

VRTX window: when it reported after the close, from that day's close to the next. Split-adjusted closes and EPS with its estimate, from Yahoo Finance. It already happened: it does not anticipate the next announcement.

Where each number comes from

From the 8-K with item 2.02 ("Results of Operations and Financial Condition") that Vertex Pharmaceuticals filed on EDGAR, the SEC's public database; only those with their 10-Q or 10-K behind them count, so other 8-Ks with the same item (production figures, monthly sales) stay out. The time is converted to New York time using this specific company's stamp convention (its EDGAR stamp arrives in UTC), and it is not assumed: it was read off the filing's official header. In 2 of this company's 66 quarters the date comes from the EDGAR acceptance day rather than the 8-K cover box, and those are flagged with an asterisk in the table.

What this data does not know

• The exact time of the press release: the 8-K reaches EDGAR minutes or hours later, so Vertex Pharmaceuticals's median 20:36 is an upper bound. The session says which one the news landed in, not what minute it was said.
• Nothing before Apr 21, 2010: it is Vertex Pharmaceuticals's oldest quarter with announcement and report paired in the file.
• What will happen. The page's only future date, Nov 2, 2026, was announced by Vertex Pharmaceuticals on the Nasdaq calendar and can be moved. Vertex Pharmaceuticals reporting after the close 35 quarters in a row does not say the next one will be the same.
• Vertex Pharmaceuticals's identity is its SEC CIK (0000875320), not its symbol: symbols get recycled and renamed.

When other Healthcare companies report earnings

• MRNA
• LLY
• INCY
• CAH
• ELV
• SOLV
• BMY
• DXCM
• CVS
• HSIC
• VTRS
• JNJ
• DVA
• UHS
• CI
• BIIB
• REGN
• CNC
• MRK
• EW
• HUM
• MCK
• COR
• AMGN
• WAT
• WST
• TECH
• ABBV
• IDXX
• DGX
• RVTY
• MTD
• A
• ZBH
• ISRG
• TMO
• ALGN
• HCA
• UNH
• COO
• BDX
• VEEV
• MDT
• DHR
• PFE
• LH
• RMD
• IQV
• GEHC
• STE
• PODD
• BSX
• SYK
• BAX
• CRL
• ZTS
• ABT
• GILD
• outside the sector
• DAL
• AFL

More on Vertex Pharmaceuticals

Vertex Pharmaceuticals is in the Healthcare sector. On the model's multifactor score of Oct 21, 2026 it ranks 123 of 464, and 15 of the 55 companies in its sector that score. It is a quantitative model ranking, not a recommendation.

Vertex Pharmaceuticals (VRTX) analysis page →

VRTX insider buys and sells →

All ~500 S&P 500 companies, sorted by when they report →

Guide: 10-K, 10-Q and 8-K · all guides

Source: EDGAR, the SEC's public database (forms 8-K, 10-Q and 10-K). Data through Aug 3, 2026. This is a list of public facts and of calculations made on them, not financial advice or a recommendation to buy or sell.